Navigation Links
Moffitt Cancer Center researchers validate molecular signature to predict radiation therapy benefit
Date:8/15/2012

Researchers at Moffitt Cancer Center, working with colleagues in Sweden, the Netherlands and Puerto Rico, have validated a radiosensitivity molecular signature that can lead to better radiation therapy decisions for treating patients with breast cancer.

The results appeared in a recent issue of Clinical Cancer Research, a publication of the American Association for Cancer Research.

The study examined patients with breast cancer who had been treated with radiation therapy and demonstrated that a radiosensitivity molecular signature (RSI) could predict clinical outcomes exclusively in patients treated with radiation therapy. The radiosensitivity molecular signature (RSI) used by the research team had previously been tested and validated for rectal, esophageal, and head and neck cancers. The technology, which identifies radiosensitivity and radioresistance, opens the door to biologically guided radiation therapy and offers the potential for better outcomes.

"Developing a radiosensitivity predictive assay has been a goal of radiation biology for decades," said Javier F. Torres-Roca, M.D., member of the Experimental Therapeutics program at Moffitt. "This effort supports the emphasis on personalized medicine, where the goal is to use molecular signatures to guide therapeutic decisions."

According to Torres-Roca, approximately 60 percent of all cancer patients receive radiation therapy during their treatment. Yet until now, no molecular diagnostic or biomarker of radiosensitivity had been developed to predict its benefit.

The radiosensitivity molecular signature was developed based on gene expression for 10 specific genes and a linear regression algorithm. RSI was developed in 48 cancer cell lines using a systems-biology strategy focused on identifying biomarkers for cellular radiosensitivity.

This study validated RSI's benefit when researchers found that radiosensitive breast cancer patients had an improv
'/>"/>

Contact: Kim Polacek
kim.polacek@moffitt.org
813-745-7408
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

0

GOOD

Page: 1 2

Related medicine news :

1. Moffitt Cancer Center researchers discover how cancer cells hijack a mechanism to grow
2. Attitudes toward outdoor smoking ban at moffitt Cancer Center evaluated
3. Moffitt Cancer Center researcher & colleagues test new drug for patients with neuroendocrine tumors
4. Moffitt Cancer Center researchers find potential key to new treatment for mantle cell lymphoma
5. Moffitt Cancer Center study validates activity of rare genetic variant in glioma
6. Moffitt researchers find cutaneous human papillomavirus infection a risk factor for skin cancer
7. Moffitt Cancer Center researchers test drug combinations to prevent graft vs. host disease
8. Sun exposure and cutaneous HPV infection found synergistic in skin cancers, Moffitt says
9. Myelodysplastic syndrome treated with deferasirox shows beneficial iron reduction, Moffitt says
10. Moffitt researchers: Darwins principles say cancer will always evolve to resist treatment
11. Moffitt researcher, colleagues find success with new immune approach to fighting some cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Approximately a year ago, the leading journal Science ... Alzheimer,s drug. A significant breakthrough and an important starting ... Bart De Strooper Alzheimer,s researcher at VIB and ... Rudi D,Hooge KU Leuven and scientists at ... various Alzheimer,s animal test models. Their results were different, ...
(Date:5/23/2013)... to be tested in a clinical trial by a ... Alzheimer,s disease has failed to work with the same ... to results of a study by University of Florida ... affiliated with the Evelyn F. and William L. McKnight ... importance of verifying promising research results before investing in ...
(Date:5/23/2013)... May 23, 2013 Dr. Katherine Ahn ... charitable organization in Orange County, OCCares , will hold ... County. The event details are as follows: , Sunday ... Auditorium, 13732 Clinton Street, Garden Grove, CA 92843 , The ... music by Christian vocalists Charmaine & Jonathan Thulin. There ...
(Date:5/23/2013)... Fort Myers, FL (PRWEB) May 23, 2013 ... daring prediction in the midst of growing numbers of H7N9 ... of UV-Aid, Predict H7N9 Bird Flu Cases Will Subside in ... of May 13th no new cases have been reported. ... of the flu is as predictable as flowers budding in ...
(Date:5/23/2013)... 23 (HealthDay News) -- Schools should ensure that ... activity each day to support their health and ... report. Although previous studies show 60 ... health and development, it,s estimated that only about ... this recommendation, according to the report from the ...
Breaking Medicine News(10 mins):Health News:New insights contradict promising Alzheimer's research 2Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 2Health News:Anti-cancer drug viewed as possible Alzheimer's treatment doesn't work in UF study 3Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 2Health News:Dr. Katherine Ahn is Proud to Announce the Launch Her Family's New Charity OCCares 3Health News:UV Technologies Bold Prediction on H7N9 in China Comes True, New Cases End Without Aid of Flu Vaccine 2Health News:UV Technologies Bold Prediction on H7N9 in China Comes True, New Cases End Without Aid of Flu Vaccine 3Health News:U.S. School Kids Should Get Hour of Exercise Daily: Report 2
... more clinical preventive services, dedicate funding source to public ... 11 Partnership for Prevention today unveiled health ... and health promotion efforts to tackle the chronic diseases ... , Under these proposals, federally ...
... Inc. (Nasdaq: PTIE ) has received a Complete Response ... New Drug Application (NDA) for REMOXY(R), an abuse-resistant controlled-release form of ... the NDA is not approved in its present form. ... non-clinical data will be required to support the approval of REMOXY. ...
... touted as the "cure" for health care, but a new ... that implementation of technology and related devices is not a ... safety of patient care. , , ... to understanding when a technology may (or may not) be ...
... Dental Management,Services, Inc. (Nasdaq: BDMS ), operators ... The Company,s board of directors,has declared a quarterly ... stock.,The dividend is payable January 9, 2009, to shareholders ... Birner Dental Management Services, Inc. acquires, develops, ...
... agonists may cause asthma problems and death, agency officials ... of four asthma medications will be weighed by a U.S. ... hearings end Thursday. , The controversy over these drugs has ... recently calling for banning the use of these drugs for ...
... PRA International, a leading,Clinical Research Organization, announces ... Mexico. With years of long-standing South American ... The region,s existing base of clinical,sites with expertise ... to PRA,s therapeutic focus. The expansion is ...
Cached Medicine News:Health News:Partnership for Prevention Offers Health Reform Recommendations to Congress 2Health News:Partnership for Prevention Offers Health Reform Recommendations to Congress 3Health News:Pain Therapeutics Receives Complete Response Letter From FDA for REMOXY(R) 2Health News:Pain Therapeutics Receives Complete Response Letter From FDA for REMOXY(R) 3Health News:Joint Commission Alert: Prevent Technology-Related Health Care Errors 2Health News:Joint Commission Alert: Prevent Technology-Related Health Care Errors 3Health News:FDA Panel Mulls Safety of Asthma Meds 2Health News:FDA Panel Mulls Safety of Asthma Meds 3Health News:PRA International Expands Operations in Mexico 2
(Date:5/23/2013)... SAN DIEGO , May 23, 2013 /PRNewswire/ ... the prostate cancer treatment continuum was highlighted prominently ... the American Urological Association (AUA), in San Diego.  ... invasive high intensity focused ultrasound (HIFU) technology, the ... localize disease, and for urologists to consider minimally ...
(Date:5/23/2013)... -- Spring Bank Pharmaceuticals, Inc., a biopharmaceutical company developing innovative ... that it has initiated dosing in a Phase I ... therapy for the treatment of HCV infection. This study will ... to assess both the safety and antiviral efficacy of ... the treatment of chronic HCV infections and is based ...
(Date:5/23/2013)... AVIV, Israel , May 23, 2013 ... BrainTech Israel 2013 , Israel,s ... place on October 14 th -15 th in ... nd most innovative city in the world by the ... "Start-up Nation." BrainTech Israel 2013 will showcase the ...
Breaking Medicine Technology:Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 2Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 3Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 4Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 5Need for Image Guided Minimally Invasive Ablative Treatments Featured Prominently at American Urological Association (AUA) Annual Meeting 6Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 2Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients 3Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 2Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference 3
... in Excess of $10 Million; Access Gains Second ... SEOUL, South Korea, Feb. 19 ... and JCOM Ltd , an ... the Republic of Korea, today announced the signing of ...
... Were Performed on AMI Patients in 2008, According to ... Millennium Research Group,s (MRG,s) US Markets for Interventional ... stents will continue to climb steadily through 2013, driven ... coronary intervention (PCI) in Acute Myocardial Infarction (AMI) patients, ...
Cached Medicine Technology:Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea 2Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea 3Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea 4Adoption of PCI in AMI Patients to Drive Drug-Eluting Stent Use 2
... provides a simple, fast and cost-effective method ... samples. This system utilizes guanidine thiocyanate and ... and denature proteins. Purified viral RNA is ... and RNase protection assays. This system is ...
... The Titertek MAP-C2 is designed for ... the instrument is the S60 Stacker that ... removable magazines. The MAP-C2 base model is ... assembly. Auxiliary Digiflex pipetting units may be ...
Grab one and go, One of the smallest handheld oximeters available, Datex-Ohmeda s TuffSat is the ideal spot-check solution for hospital, home care, transport, and EMS. TuffSat comes fully loaded wi...
The IL 682 is the Gold Standard for CO-Oximetry analysis....
Medicine Products: